Integral Health Asset Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,050,000
| Closed | -$35M | – | 102 |
|
|
2024
Q3 | $35M | Sell |
1,050,000
-50,000
| -5% | -$1.72M | 3.94% | 5 |
|
|
2024
Q2 | $29.7M | Buy |
1,100,000
+125,000
| +13% | +$2.47M | 2.82% | 8 |
|
|
2024
Q1 | $21.1M | Buy |
975,000
+75,000
| +8% | +$1.64M | 1.95% | 15 |
|
|
2023
Q4 | $5.43M | Buy |
900,000
+140,000
| +18% | +$698K | 0.74% | 55 |
|
|
2023
Q3 | $4.23M | Buy |
760,000
+162,000
| +27% | +$1.04M | 0.59% | 56 |
|
|
2023
Q2 | $4.39M | Buy |
598,000
+16,000
| +3% | +$121K | 0.54% | 57 |
|
|
2023
Q1 | $2.33M | Buy |
582,000
+339,000
| +140% | +$1.66M | 0.47% | 59 |
|
|
2022
Q4 | $792K | Buy |
243,000
+133,000
| +121% | +$534K | 0.17% | 60 |
|
|
2022
Q3 | $409K | Buy |
110,000
+52,665
| +92% | +$195K | 0.08% | 65 |
|
|
2022
Q2 | $177K | Buy |
57,335
+9,735
| +20% | +$44.8K | 0.04% | 65 |
|
|
2022
Q1 | $254K | Buy |
47,600
+17,600
| +59% | +$83.5K | 0.07% | 71 |
|
|
2021
Q4 | $146K | Hold |
30,000
| – | – | 0.04% | 71 |
|
|
2021
Q3 | $266K | Hold |
30,000
| – | – | 0.08% | 70 |
|
|
2021
Q2 | $274K | Hold |
30,000
| – | – | 0.08% | 71 |
|
|
2021
Q1 | $491K | Buy |
+30,000
| New | +$490K | 0.14% | 67 |
|
Integral Health Asset Management's LBPH Position: Q4 2024 in Review
Integral Health Asset Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 1,050,000 shares — an estimated $35M sold.
Integral Health Asset Management first reported a position in LBPH in Q1 2021 and held it in 15 quarters. The position peaked at $35M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Integral Health Asset Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Integral Health Asset Management sold 1,050,000 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $35M.
- Integral Health Asset Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- Integral Health Asset Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $35M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Integral Health Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.